Chardan Capital Predicts Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Ocugen in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of ($0.25) per share for the year. Chardan Capital currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Ocugen in a report on Thursday, March 6th.

Ocugen Price Performance

OCGN stock opened at $0.72 on Thursday. The stock has a market cap of $211.39 million, a price-to-earnings ratio of -4.02 and a beta of 3.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58. The company has a 50 day simple moving average of $0.67 and a 200 day simple moving average of $0.84. Ocugen has a 1 year low of $0.52 and a 1 year high of $2.08.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Wednesday, March 5th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share.

Institutional Investors Weigh In On Ocugen

Several hedge funds have recently added to or reduced their stakes in OCGN. Intech Investment Management LLC bought a new position in shares of Ocugen during the third quarter valued at $93,000. MetLife Investment Management LLC raised its position in Ocugen by 36.4% during the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock worth $89,000 after purchasing an additional 23,877 shares during the last quarter. State Street Corp lifted its holdings in Ocugen by 7.1% during the 3rd quarter. State Street Corp now owns 15,824,517 shares of the company’s stock worth $15,701,000 after buying an additional 1,047,896 shares during the period. Wellington Management Group LLP bought a new stake in shares of Ocugen in the 3rd quarter valued at about $456,000. Finally, XTX Topco Ltd acquired a new stake in shares of Ocugen in the third quarter valued at about $233,000. 10.27% of the stock is currently owned by institutional investors and hedge funds.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.